2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Abstract Number: 1455

Development of a Predictive Model of Radiological Damage in Patients with Rheumatoid Arthritis Based on Artificial Intelligence
Abstract Number: 1456

Neutrophil Activation Is Associated with Disease Activity and Predicts Development of Erosive Disease and Extra Articular Manifestations in Rheumatoid Arthritis
Abstract Number: 1457

Association between Disease Activity and Radiographic Progression in the Current Treat-to-Target Paradigm of Rheumatoid Arthritis: Real World Data from the Dutch Rheumatoid Arthritis Monitoring (DREAM) Registry
Abstract Number: 1458

Impact of the Joint Presence of Erosions and ACPA on Rheumatoid Arthritis Disease Activity over Time: Results from the Meteor Registry
Abstract Number: 1459

Bone Erosion Volume Changes Measured By HR-pQCT at 3-Months after Initiation of Anti-TNF Treatment Predicted Erosion Volume Changes at 1-Year in RA
Abstract Number: 1460

Plasma Mir-146a-5p Associates with Beneficial Body Composition and Plasma Metabolic Profiles in Rheumatoid Arthritis
Abstract Number: 1461

Peptidylarginine Deiminase-4 Antibodies Are Not Associated with Worse RA Activity, Symptoms or Impacts
Abstract Number: 1462

Fibrin Deposition and Neutrophil Infiltration of Rheumatoid Arthritis Synovium Are Associated with Duration of Morning Stiffness
Abstract Number: 1463

Do Anti-Citrullinated Protein Antibodies and Anti-Sjögren’s-Syndrome-Related Antigen a Double Positive Patients with Secondary Sjögren’s Syndrome and RA Have Higher Joint Disease Activity?
Abstract Number: 1464

Newer Generation Cyclic Citrullinated Peptide (CCP) 3.1 Assay in the Diagnosis of Rheumatoid Arthritis
Abstract Number: 1465

Absolute Number of Regulatory T Cells Decreased While Osteopontin Increased in Peripheral Blood of New Onset Patients with Rheumatoid Arthritis
Abstract Number: 1466

Altered Count of NK Cells and Non-Classical Monocyte Subpopulation in the Pre-Clinical Phase of Rheumatoid Arthritis
Abstract Number: 1467

Rheumatoid Arthritis Activity Monitoring and Multiplex Biomarker Verification By Tageted Proteomics
Abstract Number: 1468

Minor Salivary Gland Biopsy: Its Importance in Rheumatoid Arthritis and Secondary Sjögren’s Syndrom
Abstract Number: 1469

Measurement of Anti-Amyloid β Autoantibodies in Patients with Rheumatoid Arthritis

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].